US HHS Secretary Mike Leavitt announced that HHS has awarded a contract for $500 million to Bavarian Nordic A/S of Copenhagen, Denmark to manufacture and deliver 20 million doses of a next generation modified vaccinia Ankara (MVA) smallpox vaccine.
A close cousin of the bacterium that debilitated thousands of World War I soldiers has been isolated at UCSF from a patient who had been on an international vacation. The woman, who has since recovered, suffered from symptoms similar to malaria or typhoid fever, two infections that can occur in returning travelers.
Around half a million new cases of cervical cancer are diagnosed worldwide each year, resulting in a quarter of a million deaths, second only to breast cancer in women.
The National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), today released its NIAID Research Agenda for Multidrug-Resistant (MDR) and Extensively Drug-Resistant (XDR) Tuberculosis (TB).
CSIRO scientists have joined the battle to save Australia?s iconic Tasmanian devils from the deadly cancer currently devastating devil populations.
University of Florida researchers have begun a clinical study of oral insulin to prevent or delay type 1 diabetes in people at risk for the disease.
University Hospitals Case Medical Center (UHCMC) and Case Western Reserve University School of Medicine are part of a nationwide research study to determine the safety and effectiveness of a new smallpox vaccine geared toward adults ages 18 to 34 who have never been vaccinated against the disease.
A new test for diagnosing TB offers a quick and simple alternative to existing three-day methods, according to research published today in the journal Clinical Infectious Diseases.
Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI; Accentia) reports that the Mayo Medical and Graduate Schools and the Virginia Bioinformatics Institute have been awarded a National Institute of Health (NIH) grant of $2.4 million for a project entitled “The Pathogenesis of Chronic Rhinosinusitis.”
Adults who have recovered from the potentially deadly H5N1 strain of avian influenza may hold the key to future treatments for the virus, according to an international team of researchers.